C
Hyperuricemia
Novel & Emerging BiomarkersLab test / biomarkerriskmodifiable
12
evidence score
Also known as: Elevated serum uric acid, Hyperuricaemia, abnormally high uric acid level
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 4.8meta-analyses: 0trials: 7genetic: 0MR bonus:
References (2)
0 meta-analyses / systematic reviews- Serum uric acid and cardiovascular risk: state of the art and perspectives. — Joint bone spine 2014 · PMID 24565888
- Altered uric acid levels and disease states. — The Journal of pharmacology and experimental therapeutics 2007 · PMID 17890445
Clinical trials (4)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT04697602 | Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Patients With Gout and Hyperuricemia During the Initial Phase of Urate-lowering Therapy: an Open-label Randomized Controlled Trial | TERMINATED | INTERVENTIONAL | Stepwise dose titration of febuxostat and low-dose colchicine, Fixed dose febuxostat and low-dose colchicine |
| NCT02462421 | Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors | TERMINATED | INTERVENTIONAL | Canagliflozin |
| NCT02252835 | A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout | COMPLETED | INTERVENTIONAL | Arhalofenate, Febuxostat, Arhalofenate |
| NCT05342285 | Flow Mediated Dilation in Association With Hyperuricemia as Predictors of Cardiovascular Affection in Patients With Systemic Lupus | UNKNOWN | OBSERVATIONAL | Flow mediated dilation |
Genetic associations (0)
None linked.